| Trial ID # | NCT05194072 |
| Phase | I |
| Drug Class | Antibody Drug Conjugates: B7H4 |
| Drug Name | Felmetatug vedotin |
| Alternate Drug Names | SGN-B7H4V |
| Drugs in Trial | Felmetatug vedotin |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 86 patients in dose escalation; median 3 prior therapies (1-17), 21 OC |
| Efficacy | ORR: 20% (4PR, n=20) |
| Reference | Perez CA et al. First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Ann Oncol (2023) 34(2) abstract 660MO |